Parkinson's disease (PD) is the most common neurodegenerative motor disorder, marked by chronic progressive loss of neurons in the substantia nigra, thereby damaging purposeful control of movement. For decades, it was believed that PD was caused solely by environmental causes. However, the discovery of genetic factors involved in PD has revolutionized our attempts to understand the disease's pathology. PD now appears to be more polygenetic than previously thought and is most likely caused by a complex interaction of genetic risks and environmental exposures. The first gene found to be mutated in PD encodes for the presynaptic protein _-synuclein, which is also a major component of Lewy bodies and Lewy neurites, the neuropathological hallmarks of the disease. While these findings provide a classic example of how rare genetic mutations in disease can point to important pathways in idiopathic disease pathologies, much of the study of _-synuclein has focused on understanding how this protein undergoes the transition from an unfolded monomer to amorphous aggregates or Lewy bodylike filaments rather than addressing what its fundamental function might be. Since alterations in synuclein function may predispose to the disease pathology of PD, regardless of the presence of genetic mutations, a more thorough understanding of the cellular regulation and function of _-synuclein may be of crucial importance to our understanding of this degenerating disorder.
140 amino acid presynaptic protein, named _-synuclein, caused Parkinson's disease in families of Greco-Italian descent. _-Synuclein was first discovered in the electric organ of Torpedo (Maroteaux et al., 1988) , and localized to the presynaptic nerve terminal and nuclear membrane. Subsequently, synuclein was found to be upregulated the brains of songbirds, where it appeared to function in the seasonal development of neurons that control song learning (George et al., 1995) . It is now known that _-synuclein is a member of a family of small highly conserved proteins, including `- (Jakes et al., 1994) and a-synuclein , as well as synoretin (Surguchov et al., 1999) , that are encoded by different genes, and are enriched in the vertebrate nervous system. However to date, only _-synuclein has been implicated in PD. Adding to these discoveries was the finding that _-synuclein was a major component of Lewy bodies, the pathological hallmark in the brains of those with the disease (Spillantini et al., 1997) . Thus, while mutations in _-synuclein are rare in PD, these findings have pointed researchers toward the study of a protein that presumably has a role in the pathogenesis of idiopathic PD, as well as in other Lewy bodycontaining diseases (Goedert, 2001) . Based on this assumption, studies of _-synuclein have focused on its aggregation qualities, and animal models that may recapitulate the pathology of PD. However, many basic questions regarding the normal cell biology of this protein remain unanswered. This review is not intended as an exhaustive enumeration of the sum of literature on _-synuclein, but rather focuses on some important cell biological studies and what they may indicate about the function of this enigmatic protein.
_-Synuclein Expression and Localization
Autosomal dominant PD is similar to other familial neurodegenerative diseases, such as Alzheimer's disease and frontotemporal dementia, in which the defective gene encodes or increases the expression of the major molecular constituent of the neuropathological lesion (see Hardy and Gwinn-Hardy, 1998; Goedert, 2001 ). In the case of PD, missense mutations in the _-synuclein gene cause inherited forms of the disease (Polymeropoulos et al., 1997; Kruger et al., 1998) , and _-synuclein itself is a major component of the filamentous aggregates that accumulate in Lewy bodies in sporadic PD and other Lewy body-containing disorders (see Spillantini et al., 1997; Goedert, 2001) . Unlike these other diseases, mutations that result in increased levels of expression of _-synuclein have yet to be identified. Recent studies have demonstrated, however, that a dinucleotide repeat polymorphism (referred to as NACPRep1) located ~10 kb upstream of the translational start of _-synuclein gene (Xia et al., 1996; Touchman et al., 2001) , participates in the control of its expression (Touchman et al., 2001) . Additionally, certain alleles of the NACP-Rep1 locus have been shown to be associated with increased risk of sporadic PD (Kruger et al., 1999; Tan et al., 2000; Farrer et al., 2001) , suggesting that variable expression of the gene may play a role in the pathogenesis of the disease.
Transcription of _-synuclein appears to be developmentally regulated; in rodents, mRNAlevels peak in the first few postnatal weeks of development and then decrease thereafter (Petersen et al., 1999) . Protein levels of synuclein, however, increase during development and are sustained at fairly high levels throughout adulthood (Petersen et al., 1999) , suggesting that its levels may be controlled by as yet undiscovered post-transcriptional mechanisms. Secondary structure analysis of the 5-prime and 3-prime regions of the _-synuclein mRNAmay point to regulatory control regions that determine message stability, translatability, or targeting. In rodents (Withers et al., 1997; Hsu et al., 1998) and humans (Bayer et al., 1999; Galvin et al., 2001 ) _-synuclein protein redistributes from cell bodies to synaptic terminals in the early weeks of development in concert with other presynaptic proteins, and remains there in adults. This redistribution is likely via the association of synuclein with membranes targeted to developing synapses (Jensen et al., 1999) . Although there are subtle differences, _-synuclein appears to be expressed ubiquitously throughout the brain (Lavedan, 1998) , with synuclein mRNA levels actually lowest in the brain region most susceptible in PD, the substantia nigra (Rockenstein et al., 2001) . Interestingly, decreased synuclein mRNA levels were observed in the substantia nigra from patients with PD (Neystat et al., 1999) , raising the possibility that decreases in synuclein levels are an early change in the process leading to neuronal degeneration.
To date, no genetic modifiers of _-synuclein expression have been found; however, various cellular treatments have been shown to affect synu-clein levels, including nerve growth factor (NGF) ), 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP) (Vila et al., 2000) , certain inflammatory cytokines and cellular stress (Tanji et al., 2001) , and during megakaryocyte differentiation (Hashimoto et al., 1997) . From these data, a clearer understanding of the transcriptional and translational regulation of synuclein expression is needed before we can understand how any changes in these mechanisms may affect the disease process.
The Hydrophobic Connection
Purified _-synuclein shows little secondary structure in aqueous solution (Weinreb et al., 1996; Biere et al., 2000; Eliezer et al., 2001 ). The dominant feature of _-synuclein, however, is the presence of a series of amphipathic domains that span roughly the N-terminal two-thirds of the molecule (Fig. 1 ). Upon incubations with membranes, these domains adopt an extended alpha helical secondary structure similar to apolipoprotein class A2 molecules (Davidson et al., 1998; Eliezer et al., 2001 ) through which membrane binding becomes stabilized (Narayanan and Scarlata, 2001 ). These lipidbinding domains are conserved in all members of the synuclein family throughout all species examined. Partially included within this amphipathic region is a relatively hydrophobic stretch of amino acids, within _-synuclein's so-called NAC domain, that appears to distinguish _-from `-synuclein insofar as its capacity to form filaments in vitro and its selective inclusion within Lewy bodies (Biere et al., 2000; Giasson et al., 2001 ). The C-terminal third of _-synuclein is rich in acidic residues and likely remains free and unfolded upon membrane binding, thus providing a site for interactions with potential binding partners (Eliezer et al., 2001) (Fig. 2) .
Although much work has demonstrated a preference for _-synuclein binding to synthetic membranes containing acidic phospholipids (Davidson et al., 1998; Jo et al., 2000) , the specificity of its association with cellular membranes remains unclear. Undoubtedly, synuclein's synaptic localization indicates an affinity for synaptic membranes (Iwai et al., 1995; Withers et al., 1997; Murphy et al., 2000) . However, immunoelectron microscopy (Clayton and George, 1999) , as well as cell-fractionation studies (George et al., 1995; Irizarry et al., 1996; , suggests that synuclein is not stably associated with synaptic membranes. Although this is consistent with synuclein's structural similarity to the exchangeable apolipoproteins (George et al., 1995; Clayton and George, 1998) , the actual mechanism that regulates synuclein's association with membranes is not known. Inasmuch as the C-terminal acidic tail of synuclein appears dispensable for membrane binding (Perrin et al., 2000) , it is likely that post-translational modifications such as phosphorylation that can occur on Ser 129 (Okochi et al., 2000; Pronin et al., 2000) and/or Tyr 125 (Ellis et al., 2000; Nakamura et al., 2001) , do not influence synuclein's ability to bind membranes directly (Narayanan and Scarlata, 2001) . These modifications may, however, influence the kinetics of membrane binding or modulate synuclein's association Fig. 1 . Schematic organization of _-synuclein. The coding region of _-synuclein is 140 amino acids long and contains seven repeats (striped boxes) of a degenerate 11-residue consensus sequence, pKTKEGVaxaA, where p represents a polar residue, a represents an apolar residue, and x represents any residue. These amphipathic repeats likely form five alpha helices that resemble the class A2 family of apolipoproteins, with the indicated threonine residues in the center of the apolar face (Perrin et al., 2000) . The two PD-linked mutations (A30P and A53T) are indicated. The NAC domain is the portion of _-synuclein identified from neuritic plaques in Alzheimer's disease (Ueda et al., 1993) . Within this domain, repeat six is entirely hydrophobic and deviates from the consensus sequence of the other repeats . Also within the NAC domain, _-synuclein contains eleven residues specifically absent in `-synuclein (amino acids 73-83). with various binding partners that then regulate membrane association. Determining the kinetics of synuclein's membrane on/off rate, therefore, in both purified and cellular systems is likely important for understanding not only its normal function, but in determining if alterations in this rate are affected by PD mutations that may influence synuclein's propensity for aggregation (see below). In this regard, the PD mutant A30P shows slightly reduced binding to synthetic membranes compared with wild-type synuclein (Perrin et al., 2000) , and binds significantly less well to specific membrane compartments within intact cells (Cole et al., 2002) . In contrast, the A53T mutation likely increases synuclein's affinity for membranes (Sharon et al., 2001; Cole et al., 2002) . Since purified Lewy bodies contain lipid components (Gai et al., 2000) , the possibility exists that if membrane binding is important in Lewy body formation, the different PD mutants cause disease by nonidentical mechanisms.
Based on in vitro binding experiments (Davidson et al., 1998; Perrin et al., 2000) , it is likely that synuclein's association with synaptic membranes is regulated by the lipid composition of the membranes themselves. In vitro evidence suggests that synuclein may function as a negative regulator of the PIP2-dependent activation of phospholipase D2 (Jenco et al., 1998) , and that phosphorylated forms of synuclein may modulate PLD2 activity (Pronin et al., 2000) . Given the key role of phosphoinositides in a variety of synaptic processes (Osborne et al., 2001) , synuclein may preferentially associate with or regulate the maintenance of ordered membrane microdomains and serve to regulate synaptic membrane signaling and/or morphogenesis. Although phosphorylation of _-synuclein has yet to be documented in brain, synuclein's ability to be phosphorylated by G-protein coupled receptor kinases (GRKs; (Pronin et al., 2000) and the Src family of nonreceptor tyrosine kinases (Ellis et al., 2000; Nakamura et al., 2001 ) in vitro and in culture systems support a role for synuclein in synaptic signaling pathways.
A more direct role for synuclein in modulating synaptic membrane morphogenesis is suggested by observations demonstrating a reduction in synaptic vesicle pools in the hippocampus of both antisense-treated cultured neurons (Murphy et al., 2000) and _-synuclein knockout mice (Cabin et al., manuscript submitted) . In addition, synuclein has recently been proposed to act as a fatty acid binding protein (FABP) (Sharon et al., 2001) . One function of the FABPs is to ferry free fatty acids between aqueous and membrane-bound compartments for a variety of purposes, including phospholipid synthesis, hydrolysis, and storage (see Storch and Thumser, 2000) . Although structurally dissimilar to FABPs (Hertzel and Bernlohr, 2000) , or other known nonspecific lipid transfer proteins (Choinowski et al., 2000) , synuclein may undergo conformational changes upon fatty acid binding that allows it to transiently deliver lipids to various subcellular compartments. Functional analysis of fatty acid uptake and transport (e.g., conversion to phospholipids, triglycerides, etc.) needs to be performed in cell-or animal-based systems before synuclein's role as a bona-fide FABP can be concluded. Synuclein has also been proposed to function as a molecular chaperone that prevents denaturation of selected proteins Souza et al., 2000b) . This is likely to occur via synuclein's ability to bind to and stabilize hydrophobic domains that become exposed during protein denaturation. Given its well-known capacity to bind lipids, one possibility is that synuclein may act as a type of chaperone, not by binding to exposed hydrophobic domains in unfolded proteins, but by interacting with the hydrophobic domains of the membranes themselves. This 'lipid chaperone' function may normally serve to protect neuronal membranes from oxidative damage, since synaptic vesicles are enriched in phospholipids containing polyunsaturated acyl chains that are uniquely sensitive to lipid peroxidation (Deutsch and Kelly, 1981; Moore and Roberts, 1998; Refsgaard et al., 2000) . By this mode of action, synuclein may also serve as a possible sink for reactive aldehyde groups generated by lipid peroxidation (Mattson, 1998) and may offer one explanation for the high relative abundance of synucleins in nervous tissue (Shibayama-Imazu et al., 1993; Iwai et al., 1995) .
Synuclein Oligomerization
Although the major component of Lewy bodies and Lewy neurites are 50-700 nm long filaments composed of _-synuclein (Arima et al., 1998; Spillantini et al., 1998) , it remains unclear whether these insoluble aggregates are themselves the toxic species in PD, or whether oligomeric precursors Wood et al., 1999) or so-called protofilaments (see Goldberg and Lansbury, 2000) are most important in the establishment of disease. What is becoming clear, however, is that filament assembly is a nucleation-dependent process (Wood et al., 1999) and occurs via the amphipathic domains in the N-terminus of the protein . In addition, this process appears to progress through partially folded intermediates that, at least in vitro, form under a wide variety of conditions (see Uversky et al., 2001a) . Covalent stabilization and accumulation of these intermediates may then serve to nucleate subsequent fibril formation (Wood et al., 1999; Conway et al., 2000) . The sizes of these intermediates likely include small oligomers, particularly dimers and trimers (Jensen et al., 1997; Baba et al., 1998; Hashimoto et al., 1998; Langston et al., 1998; Campbell et al., 2001) , and their formation Fig. 2 . Schematic representation of the transition of _-synuclein from a natively unfolded molecule in solution to one adopting an alpha-helical conformation in the presence of membranes. Shown is an expanded portion of the lipid bilayer from a synaptic vesicle. When associated with lipid, the nonpolar face of the amphipathic domain is buried deep into the hydrophobic interior of the lipid monolayer. The stars indicate the interfacial lysine residues that increase the lipid affinity of the amphipathic helices and help anchor the helix in the lipid bilayer (Mishra and Palgunachari, 1996) . The acidic C-terminal tail remains free and unstructured (Eliezer et al., 2001) . What determines synuclein's membrane on/off rate, and whether PD mutations affect the kinetics of this process are not known. Also unclear is the relationship between membrane binding and synuclein oligomer/filament formation (see text).
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likely results in partial conversion of synuclein tò -sheet rich structures (Volles et al., 2001 ). Descriptions of possible branched pathway intermediates that lead either to fibril formation or to amorphous aggregates (Uversky et al., 2001c) are still incomplete, however, as well as whether aggregation of PD mutants proceeds by identical pathways as wildtype synuclein.
Uversky and colleagues have illustrated that natively unfolded proteins are generally characterized by a combination of low overall hydrophobicity and large net charge. Thus, any alterations in a protein's environment leading to an increase in its hydrophobicity and/or decrease in its net charge are likely to lead to partially folded conformations (Uversky et al., 2000) . Thus, it is not surprising that many of the molecules shown to induce conformational changes in synuclein affect these parameters. Clearly, membrane binding is the most significant; this results in the conversion of a natively unfolded molecule to one with a modular structure composed of alpha helices positioned within the N-terminal two-thirds of the molecule and an unstructured and exposed acidic C-terminus (Davidson et al., 1998; Jo et al., 2000; Eliezer et al., 2001) . Additional alterations in synuclein structure have been shown to be directed primarily by nonpolar interactions and include its binding to fatty acids (Perrin et al., 2001; Sharon et al., 2001) , hydrophobic pesticides (Uversky et al., 2001c) and dyes (Shin et al., 2000; Lee et al., 2001a) , organic solvents , hydrophobic peptides (Paik et al., 1998) , and exposed domains of partially denatured proteins Souza et al., 2000b) . Concurrently, decreases in synuclein's net charge are likely to result from exposure to metals that reduce electrostatic repulsion within synuclein's acidic C-terminus (Paik et al., 1999; Uversky et al., 2001b) . The conformational intermediates that form under these conditions are in equilibrium with natively unfolded synuclein, and presumably any mechanism(s) that stabilizes these structures would lead to highly populated and potentially toxic intermediates. This likely includes the formation of crosslinked synuclein oligomers generated under oxidative stress conditions, such as the formation of dityrosine crosslinks (Souza et al., 2000a) , and lipid peroxidation-generated adducts (Mattson, 1998; Perrin et al., 2001) . Interestingly, within cell extracts synuclein oligomers appear to preferentially associate with membranes rather than in the cytosol (Lee et al., 2001c) (Cole et al., 2002) , and thus may be formed via lipid peroxidation-based crosslinking of the numerous lysine residues positioned at the membrane/cytosol interface of membrane-bound synuclein Lee et al., 2001c; Perrin et al., 2001) . It is therefore important to determine the role of membranes in Lewy body formation. Is the "seed" in Lewy body formation initiated by membrane-bound or cytosolic synuclein, and does synuclein oligomerization precede membrane binding, or are oligomers generated subsequent to the conformational alterations that occur in the synuclein monomer after binding to membranes?
One major unanswered question concerns the selective degeneration of dopaminergic neurons in the substantia nigra of patients with PD. Similar loss of neurons has been observed in brains of flies expressing wild-type and PD mutant synucleins (Feany and Bender, 2000) and in rats with chronic exposure to the pesticide rotenone (Betarbet et al., 2000) . Much work has focused on the role of excessive oxidative stress generated by oxidation of the endogenous neurotransmitter dopamine, the formation of neuromelanin, and the presence of high concentrations of iron in the substantia nigra (Zhang et al., 2000a; Barzilai et al., 2001) . Recently, Lansbury and colleagues demonstrated that synuclein fibrillization could be reduced and the proportion of synuclein oligomers/protofibrils increased in the presence of oxidized forms of dopamine and dopamine-related compounds (Conway et al., 2001 ). These compounds likely mediate the formation of synuclein-dopamine adducts and result in the formation of synuclein cross-linked oligomers incapable of progressing into synuclein fibers. Whether dopamine-based synuclein adducts are generated in vivo is unknown, as is the structural relationship between these synuclein oligomers/protofilaments and oligomers generated by other oxidative mechanisms (see above). Depending on whether synuclein filaments or oligomers/protofilaments are the toxic species in PD, it is unclear whether therapies based on targeted lowering of dopamine would be beneficial or detrimental.
Synuclein Binding Partners
Aside from its inherent lipid binding properties, _-synuclein has been shown to interact with a number of proteins, through which their individ-ual activities may be modulated. As mentioned earlier, _-synuclein (as well as `-synuclein) was shown to inhibit the activity of PLD2 in vitro (Jenco et al., 1998) . Although direct binding of synuclein with PLD2 was not determined (Jenco et al., 1998) , nor has an effect synuclein on PLD2 activity in cells or cell extracts been reported, this attractive observation fits with data for a potential role for synuclein in membrane trafficking events at the neuronal synapse. A direct interaction was observed between the NAC domain of _-synuclein and the C-terminal tail of the presynaptic human dopamine transporter (hDAT) (Lee et al., 2001b) . Functionally, this interaction enhanced delivery of hDAT from internal membrane compartments to the cell surface and accelerated cellular dopamine uptake. Although synuclein did not colocalize with plasma membrane-associated hDAT as might be expected for a stable interaction, these results provide further evidence for a role for synuclein in membrane trafficking of synaptic membrane proteins. Whether localization of the DAT is altered in synuclein knockout or PD mutant mice is therefore an important question, as is the role of synuclein in dopamine neurotransmitter uptake and release (Abeliovich et al., 2000) .
The first protein shown to physically bind to _-synuclein, termed synphilin-1, was revealed by a yeast two-hybrid study (Engelender et al., 1999) . Synphilin-1 is a novel 90 kDa cytoplasmic protein of unknown function with several ankyrin-like repeats, and a coiled-coil domain; thus one proposed function of synphilin-1 is as an adaptor protein to anchor _-synuclein to intracellular proteins involved in vesicle transport and cytoskeletal function (Engelender et al., 1999) . Synphilin-1 binds to synuclein primarily within synuclein's N-terminal amphipathic domain (amino acids 1-39) (Engelender et al., 1999) . Whether synuclein is capable of binding simultaneously to both synphilin-1 and membranes is unknown. Coexpression of synphilin-1 with the NAC domain (amino acids 61-95) of _-synuclein, but not the full-length protein, induced the formation of phase dense eosinophilic cytoplasmic inclusions in a small percentage of cells (Engelender et al., 1999) . How the NAC domain induced these synphilin-1 inclusions in the apparent absence of direct binding (Engelender et al., 1999) is not clear. Also somewhat contradictory are more recent findings from the same group that fulllength synuclein was capable of forming cytoplasmic inclusions when coexpressed with synphilin-1 (Chung et al., 2001) . Whether the formation of these inclusions is due to synphilin-1-induced structural changes in synuclein that predispose it to oligomerization/aggregation is not known (see above).
Recently, synphilin-1 was shown to bind and be ubiquitinated by the E3 ubiquitin-protein ligase, parkin (Chung et al., 2001) . Mutations in parkin cause autosomal-recessive juvenile-onset PD (AR-JP) (Kitada et al., 1998) , most likely by disrupting its E3 ubiquitin-protein ligase activity (Imai et al., 2000; Shimura et al., 2000; Zhang et al., 2000b) . For reasons that are not clear, synphilin-1 shows a higher affinity for parkin that contains familial-associated mutations than the wild-type protein (Chung et al., 2001) . Interestingly, these mutations are clustered in the same region of parkin (the IBR and C-terminal R2 ring-finger domains) that interacts preferentially with synphilin-1. The raises the possibility that the lack of Lewy bodies in patients with particular mutations in parkin may be due to sequestration of parkin and synphilin-1 into aggregation-incompetent complexes. Parkin can be detected in some Lewy bodies (Shimura et al., 1999; Choi et al., 2001 ) and the absence of Lewy bodies in patients with parkin mutations indicates that parkin may be required for Lewy body formation (Mori et al., 1998; Hayashi et al., 2000) . These findings potentially link two familial associated PD genes, _-synuclein and parkin, via the synuclein-interacting protein synphilin-1, in the ubiquitination of proteins found in Lewy body-like inclusions. Like synuclein, synphilin-1 is found in Lewy bodies; interestingly, however, synphilin-1 is not found in Lewy neurites , suggesting that synphilin-1 is not necessary for the formation of all synuclein-positive aggregates in vivo. In addition, the lack of synphilin-1 in synuclein-positive Lewy neurites that may also contain ubiquitin (Gai et al., 1995; Wakabayashi et al., 1997) raises the still unresolved issue of whether synuclein itself is ubiquitinated, and whether ubiquitin-targeted proteasomal degradation is the mechanism for synuclein turnover (see below).
Based on coimmunoprecipitation data and functional analysis, synuclein has been proposed to function as a member of the 14-3-3 family of chaperones, operating as a molecular scaffold that stabilizes the conformations of selected binding partners (Ostrerova et al., 1999) . Interestingly, crystal structures for several 14-3-3 isoforms have been deter-mined. Each 14-3-3 monomer is composed of nine antiparallel alpha helices that form homodimers with a deep large channel in the center of the complex. The walls of this channel contain amphipathic grooves in which peptides or protein domains that contain phosphoserine or phosphothreonine residues can bind (Fu et al., 2000; Obsil et al., 2001) . Since coimmunoprecipitation of synuclein with 14-3-3 proteins and their binding partners was performed in the presence of detergent micelles, the results of Ostreova and colleagues raise the possibility that synuclein may structurally resemble this complex in an analogous fashion; that is, by binding to proteins through the formation of extended alpha helices between two synuclein monomers. This could occur under conditions in which synuclein's N-terminal domains form amphipathic alpha helices, such as in the presence of detergent micelles or within cells when synuclein is membrane-bound. Whether synuclein can exist as dimers in membranes and with a similar orientation found in 14-3-3 proteins is unknown, as are questions regarding synuclein's capacity to interact with additional proteins through its amphipathic domains when it is membrane-bound. To determine the specificity of these interactions, it would be interesting to test synuclein's interactions with 14-3-3 family members and their binding partners using purified proteins in the absence and presence of detergent micelles or purified cell membranes.
Synuclein Turnover
The concept that the accumulation of intracellular proteins due to alterations in their folding and/or degradation leads to neurodegeneration in both familial and sporadic cases of PD has received general support. Indeed, genetic and biochemical evidence suggests that ubiquitin-dependent proteasomal degradation may be impaired in a number of neurodegenerative diseases, including PD (see Layfield et al., 2001; McNaught et al., 2001) . The presence of polyubiquitin chains rather than ubiquitin monomer in purified Lewy bodies from patients with diffuse Lewy body disease supports this view (Iwatsubo et al., 1996) . What remains unclear is whether synuclein itself is polyubiquitinated and if ubiquitin-mediated proteasomal degradation is its normal mode of disposal. Alternatively, if synuclein is not ubiquitinated, is it still degraded by the proteasome, as has been found for some nonubiquitinated proteins (Ciechanover, 1994; Hochstrasser, 1995) , or is it degraded in lysosomes or by the other major nonlysosomal proteases, the calpains (Melloni and Pontremoli, 1989; Chan and Mattson, 1999) ? Given that synuclein's half-life is almost 2 d (Okochi et al., 2000; Paxinou et al., 2001) , acute regulation of synuclein levels is unlikely. Nevertheless, the failure to properly degrade synuclein by whatever mechanism(s) is likely an ultimate cause for its accumulation in numerous Lewy bodycontaining diseases.
Although a direct interaction between synuclein and synphilin-1 is somewhat clear (Engelender et al., 1999; Chung et al., 2001 ), synuclein's interaction with parkin is less so. Shimura and colleagues (2001) demonstrated parkin's interaction with a novel 22-kDa O-linked glycosylated form of synuclein from human brain, but not the abundant 14-kDa monomer. In an in vitro ubiquitination assay wildtype parkin, but not AR-JP mutants defective in binding either 22-kDa synuclein or parkin's E2 ubiquitin-conjugating enzyme UbcH7, modified the 22-kDa synuclein into polyubiquitinated high molecular-weight species (Shimura et al., 2001) ; within cells, these would presumably be targeted for proteasomal degradation. These results suggest that it is the 22-kDa form of synuclein that is a preferred substrate for parkin, and its accumulation in familial AR-PD is the major cause of pathology. Whether 22-kDa synuclein exists in Lewy bodies from idiopathic PD is unknown. In contrast to Shimura and colleagues, only nonglycosylated synuclein could be immunoprecipitated with parkin in human brain extracts and BE-M17 neuroblastoma cells (Choi et al., 2001) , and neither form of synuclein associated with parkin in HEK293 cells or the human neuronal cell line SH-SY5Y (Chung et al., 2001) , or in rat brain (Fallon et al., 2001) . Whether nonglycosylated synuclein in the experiments by Choi and colleagues is also a substrate for parkin's ubiquitin-ligase activity needs to be explored. Recent evidence suggests that parkin contains a PDZ binding motif at its extreme C-terminus, and interacts primarily with Triton X-100 insoluble postsynaptic proteins in rat brain extracts (Fallon et al., 2001 ). This would seem to indicate that a physiological interaction between parkin and presynaptic synuclein is unlikely. Whether parkin's interaction with synuclein occurs in other parts of the cell is unknown (see below). Clearly, this issue needs to be clarified, since the apparent lack of Lewy bodies in AR-JP indicates that one or more parkin substrates needs to be effectively ubiquinitated/degraded to prevent disease (Mori et al., 1998; Hayashi et al., 2000) .
The data from Shimura and colleagues (2001) suggest that synuclein, albeit only its glycosylated form is polyubiquitinated and targeted for degradation by the proteasome. Other investigators, however, have found that synuclein is not ubiquitinated (Ancolio et al., 2000) , and synuclein's degradation by the proteasome has been questioned (Bennett et al., 1999; Ancolio et al., 2000; Paxinou et al., 2001; Rideout et al., 2001 ). In addition, data from a number of studies indicate that in several Lewy body disorders, the number of _-synuclein positive structures exceeds those that stain with anti-ubiquitin antibodies Gomez-Tortosa et al., 2000; Hurtig et al., 2000) . Although comparisons of epitope accessibility between different antibodies are difficult to quantify, especially in cellular aggregates, these results suggest that the accumulation of _-synuclein precedes the appearance of ubiquitin in these structures. Thus, under pathological conditions, synuclein aggregation is likely not the result of a higher propensity for ubiquitinated synuclein to form oligomers/aggregates, but that ubiquitination may be simply a postaggregation cellular response to attempt to eliminate the inclusion. If this turns out to be the case, modification of synuclein by ubiquitin and subsequent degradation by the proteasome may not be its mode of turnover under normal cellular conditions. Some clues regarding the fate of synuclein may be obtained by determining the location within neurons where synuclein is ultimately degraded. Antibodies to proteasomal subunits label presynaptic boutons in selected nerve populations from rat Central nervous system (CNS) (Mengual et al., 1996) , and degradation of cytosolic synaptic proteins can occur locally (Li et al., 1995; Li et al., 1997) . This raises the possibility that a proportion of synuclein may be degraded within the synapse. However, optic nerve-ligation experiments suggest that the bulk of synuclein is transported retrogradely on membranes from the synapse to the cell body (Jensen et al., 1999) . These membranes may then undergo degradation through the process of autophagy followed by fusion with lysosomes, which is the major mechanism for regulated turnover of cellular organelles (Klionsky and Emr, 2000) . Consistent with this, accumulations of synuclein within the cell bodies of primary hippocampal cultures from transgenic mice overexpressing A53T mutant human synuclein colocalized with the lysosomal membrane marker LAMP-1 (Gispert et al., manuscript submitted). Interestingly, no such accumulations could be observed in neurons from mice expressing wildtype human synuclein, suggesting that pathogenic alterations in synuclein's structure may affect its ability to be effectively degraded. Whether these A53T synuclein-containing cell body inclusions are derived from membranes retrogradely transported from the synapse or from reduced anterograde transport needs to be determined. Lysosomes, but not the proteasome have also been implicated in synuclein turnover in HEH293 cells, since treatment with the acidotropic agent ammonium chloride increased the steady-state levels of synuclein, whereas the proteasome inhibitor lactacystin had no effect, nor did lactacystin induce the formation of synucleinpositive ubiquitin-containing aggregates (Paxinou et al., 2001) . Whether synuclein accumulates in lysosomes upon treatment with ammonium chloride was not reported.
Potential Functions of _-synuclein/
Conclusions?
The primary site of _-synuclein function is most likely presynaptic, as it can be isolated from synaptic-membrane fractions and localizes near and around the vesicles of the presynaptic terminal (Clayton and George, 1999) . Inactivation of the _-synuclein gene by homologous recombination does not lead to a significant neurological phenotype, although changes in dopaminergic electrophysiology may reflect a specific function related to neurotransmitter release (Abeliovich et al., 2000) . When _-synuclein expression is markedly reduced in cultured rat neurons (Murphy et al., 2000) , or abolished in _-synuclein knockout mice (Cabin et al., manuscript submitted), the number of vesicles in the distal pool of the presynaptic terminal is reduced. This further suggests a role for synuclein in vesicular dynamics, perhaps through its potential to interact with specific lipids in synaptic membranes. Given synuclein's propensity to bind molecules with high hydrophobic content or exposed hydrophobic domains, a role for synuclein in lipid metabolism appears likely. This could occur either by modulating synaptic lipid content directly or indirectly via the trafficking of membranes either
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within the synapse or between the synapse and the cell body. One difficulty in understanding the function of synuclein is the inherent flexibility of the synuclein monomer and its altered conformation in the presence of lipids. For example, one important question regarding potential synuclein binding partners is whether they bind synuclein in its membrane-bound (modular) or free (natively unfolded) state, or both. Possibly more critical as far as synuclein selfassembly or filament formation is concerned is the whether the stability of these interactions influences the kinetics of synuclein's normal association with membranes, and do alterations in membrane binding play a role in the initiation of aggregates in both familial and idiopathic PD? Investigation into synuclein function may be complicated by the structural alterations that synuclein appears to undergo in the presence of detergent micelles (Weinreb et al., 1996; Eliezer et al., 2001 ). Since it is unclear whether detergent-associated synuclein structurally mimics its membrane-bound form, coimmunoprecipitation experiments traditionally performed in the presence of these detergents may result in identification of binding partners not normally associated with synuclein physiologically. They may also fail to reveal bona-fide synuclein binding partners for similar reasons. Likewise, although the unstructured acidic C-terminus of synuclein is a likely site for interaction with additional proteins, nonspecific electrostatic interactions might lead to potentially false avenues of investigation. Therefore, persuasive evidence of a role for synuclein in any particular pathway or function likely requires multiple approaches.
Transgenic animal models of PD based on synuclein overexpression have so far revealed little in the way of understanding synuclein's normal function. However, suppressor analysis from transgenic flies expressing wild-type or PD mutant synucleins (see Feany and Bender, 2000) will likely provide valuable information on mechanisms of synuclein aggregation and toxicity, as well as significant insight as to why wild-type synuclein in vertebrates remains for the most part soluble under nonpathological conditions. Similarly, synuclein expression in lower eukaryotes (e.g., yeast) may provide clues as to its normal function, as well as how its dysregulation may affect neuronal physiology in higher organisms.
The discovery of synuclein mutations in familial PD marked a turning point of cultural change in the study of PD pathogenesis. As such, it is an example what is becoming more common in neurodegenerative disease research: giant leaps forward in genetic discovery that demand careful and more time-consuming follow-up of the cell biology of proteins implicated by such discovery. While therapeutic strategies for PD initially revolve around understanding synuclein aggregation, a clearer understanding of the basic cell biology of this protein will advance our understanding of the cellular pathways involved in PD and the role of other proteins that have since been implicated through genetic findings, and define a system for which the impact of environmental triggers for PD may be more systematically evaluated.
